Literature DB >> 18683474

Arginine vasopressin in the treatment of vasodilatory septic shock.

Cheryl L Holmes1, Keith R Walley.   

Abstract

Vasodilatory septic shock is characterized by profound vasodilation of the peripheral circulation, relative refractoriness to catecholamines and a relative deficiency of the posterior pituitary hormone, vasopressin. Arginine vasopressin is effective in restoring vascular tone in vasodilatory septic shock and may be associated with decreased mortality in less severe septic shock as well as improved mortality and decreased renal failure in septic shock patients at risk for renal failure.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18683474     DOI: 10.1016/j.bpa.2008.03.002

Source DB:  PubMed          Journal:  Best Pract Res Clin Anaesthesiol        ISSN: 1521-6896


  5 in total

1.  Vasopressin Plasma Concentrations Are Not Associated with Hemodynamic Response to Exogenous Vasopressin for Septic Shock.

Authors:  Jason R Yerke; Gretchen L Sacha; Rachel G Scheraga; Daniel A Culver; Susamma Abraham; Heather Torbic; Simon W Lam; Mahmoud A Ammar; Mitchell A Olman; Seth R Bauer
Journal:  Pharmacotherapy       Date:  2019-11-28       Impact factor: 4.705

Review 2.  Sepsis in pregnancy and early goal-directed therapy.

Authors:  Julie Joseph; Aneeta Sinha; Michael Paech; Barry N J Walters
Journal:  Obstet Med       Date:  2009-09-01

3.  The prevention of acute kidney injury an in-depth narrative review: Part 2: Drugs in the prevention of acute kidney injury.

Authors:  Norbert Lameire; Wim van Biesen; Eric Hoste; Raymond Vanholder
Journal:  NDT Plus       Date:  2009-02

4.  Low-dose vasopressin infusion results in increased mortality and cardiac dysfunction following ischemia-reperfusion injury in mice.

Authors:  Toonchai Indrambarya; John H Boyd; Yingjin Wang; Melissa McConechy; Keith R Walley
Journal:  Crit Care       Date:  2009-06-23       Impact factor: 9.097

Review 5.  Vasoplegia in patients with sepsis and septic shock: pathways and mechanisms.

Authors:  A-M Burgdorff; M Bucher; J Schumann
Journal:  J Int Med Res       Date:  2018-01-14       Impact factor: 1.671

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.